Dose-effect And Immunological Mechanism Of Astragalus Membranaceus Combined With Madopar For Parkinson’s Disease With Qi Deficiency

Objective:By studying the effects of single Astragalus membranaceus(AM)on Parkinson’s Disease patients with Qi-deficiency type by Unified-Parkinson Disease Rating Scale(UPDRS)Ⅲ,Parkinson’s Disease Quality of Life Scale(PDQ-39)and the immune status of peripheral blood mononuclear cells(PBM),to explore whether single astragalus can improve the motor symptoms and living quality of PD patients with Qi deficiency.And whether it can down-regulate the immune activity of PBM.Content:In this study,128 patients with Qi-deficiency PD were enrolled.Through the determination of UPDRS-Ⅲ score,PDQ-39 score and PBM immune status of the study cases before treatment and 8 weeks after treatment,the clinical efficacy of single AM in the treatment of Qi-deficiency PD was verified,and the function mechanism was preliminarily studied,that is,the influence of single AM on PBM immune status.Methods:According to the inclusion criteria,128 patients with Qi-deficiency PD were randomly divided into 4 groups,with 32 cases in each group.The one control group was given conventional medoba.In addition to taking metoba,patients in the three observation groups were given different doses(30g,60 g,120g)of Astragali water decoction,warm twice a day.At the same time,30 gender-and age-matched caregivers of PD patients were included as normal control group.After the 8-week treatment course,the UPDRS-Ⅲ and PDQ-39 score of the patients before and after therapy were compared by using SPSS26.0 data analysis software.The contents of inflammatory factor TNF-αand IL-1β and the contents of TNF-α and IL-1β after restimulation in every group before and after theray was checked by ELISA,and to analyze and explore the effect of single AM on UPDRS-Ⅲ score,PDQ-39 score and peripheral immune status in patients with Qi-deficiency type PD.Results:1.A total of 120 patients completed the clinical study after the removal and elimination of cases.The total shedding rate was 6.25%.2.After treatment,the UPDRS-Ⅲ score and PDQ-39 score of the 30 g,60g,and 120 g groups of AM were significantly lower than those of the PD control group(P<0.05).There was no significant difference between the different dosage groups of AM(P>0.05).3.The contents of TNF-α and IL-1β in PD patients were significantly higher than those in normal control group,with statistical difference(all P<0.01).There were no significant differences in the contents of TNF-α and IL-1β in PD control group,AM 30 g group,60 g group and 120 g group before and after treatment(all P>0.05).4.There were no significant differences in the contents of TNF-α and IL-1β after PBM inflammatory stimulation in PD control group before and after treatment(P>0.05),but there were significant differences in the contents of AM 30 g group,60 g group and 120 g group(all P<0.01).The levels of TNF-α and IL-1β after PBM restimulation in AM groups after treatment were significantly decreased compared with PD control group,and decreased with the increase of AM dosage,with statistical differences among all groups(all P<0.05).Conclusion:Compared with metoba alone,the UPDRS-Ⅲ score and PDQ-39 score of patients were more significantly decreased by taking Astragali water decoction,and the levels of TNF-α and IL-1β were decreased after PBM restimulation.The inhibitory effect was positively correlated with the dosage of AM.